RIGLRigel Pharmaceuticals, Inc.
$48.76+65% 1Y
$48.76
$25.4452 weeks$50.96
RIGL in its own filings
RIGL's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
419
Events found in the filings · across 1,462 filings · the record starts in 2001
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 30, 2001
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Delisting notice / listing-rule failure3 occurrences
- 2023-11-30
- SEC comment-letter activity25 occurrences
- 2024-08-08
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Rigel Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 1, 2026On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.Director or officer change · Form 8-K
- Jun 17, 2026As previously disclosed in the Current Report on Form 8-K filed by Rigel Pharmaceuticals, Inc. (the “Company”) on May 12, 2026, the Company entered into a License Agreement (the “License Agreement”) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the …Acquisition or disposition completed · Form 8-K
- May 20, 2026Approval of Equity Compensation Plans Approval of 2018 Equity Incentive Plan, As Amended On May 14, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Rigel Pharmaceuticals, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2018 Equity Incentive Plan, as …Director or officer change · Form 8-K
- May 12, 2026On May 11, 2026, Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”) entered into a License Agreement (the “Agreement”) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the “Licensors”)Material agreement entered · Form 8-K
- May 5, 2026Rigel Reports First Quarter 2026 Financial Results.Earnings release · press release
- Apr 21, 2026On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.Material agreement terminated · Form 8-K
- Mar 3, 2026Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Feb 3, 2026On February 1, 2026 (the “Effective Date”), Michael P. Miller was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”), upon the recommendation of the Board’s Corporate Governance, Health Care Compliance Oversight and Nominating Committee, until his …Director or officer change · Form 8-K
- Dec 10, 2025On December 7, 2025, Rigel Pharmaceuticals, Inc. (“Rigel”) announced certain data from its ongoing Phase 1b study evaluating R289 in lower-risk myelodysplastic syndrome.Other event · Form 8-K
- Nov 4, 2025Rigel Reports Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…